Nuveen Asset Management LLC Sells 10,221 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

Nuveen Asset Management LLC lowered its position in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) by 10.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 87,097 shares of the biotechnology company’s stock after selling 10,221 shares during the quarter. Nuveen Asset Management LLC owned approximately 0.32% of Arcturus Therapeutics worth $1,478,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Virtus ETF Advisers LLC increased its stake in shares of Arcturus Therapeutics by 38.8% in the 4th quarter. Virtus ETF Advisers LLC now owns 4,051 shares of the biotechnology company’s stock valued at $69,000 after acquiring an additional 1,132 shares during the last quarter. KLP Kapitalforvaltning AS bought a new stake in shares of Arcturus Therapeutics in the 4th quarter valued at about $71,000. National Bank of Canada FI increased its stake in shares of Arcturus Therapeutics by 639.6% in the 4th quarter. National Bank of Canada FI now owns 5,532 shares of the biotechnology company’s stock valued at $94,000 after acquiring an additional 4,784 shares during the last quarter. Kennedy Capital Management LLC increased its stake in shares of Arcturus Therapeutics by 22.7% in the 4th quarter. Kennedy Capital Management LLC now owns 10,987 shares of the biotechnology company’s stock valued at $186,000 after acquiring an additional 2,036 shares during the last quarter. Finally, SG Americas Securities LLC grew its position in shares of Arcturus Therapeutics by 45.0% in the 4th quarter. SG Americas Securities LLC now owns 11,940 shares of the biotechnology company’s stock valued at $203,000 after purchasing an additional 3,705 shares during the period. Institutional investors own 94.54% of the company’s stock.

Arcturus Therapeutics Stock Up 1.5%

Shares of NASDAQ ARCT opened at $13.00 on Wednesday. The firm has a market capitalization of $352.57 million, a P/E ratio of -5.86 and a beta of 2.36. The stock’s 50-day simple moving average is $11.33 and its two-hundred day simple moving average is $14.68. Arcturus Therapeutics Holdings Inc. has a twelve month low of $8.04 and a twelve month high of $45.00.

Arcturus Therapeutics (NASDAQ:ARCT) last announced its quarterly earnings data on Monday, May 12th. The biotechnology company reported ($0.52) EPS for the quarter, beating the consensus estimate of ($1.58) by $1.06. The firm had revenue of $29.38 million for the quarter, compared to analyst estimates of $25.64 million. Arcturus Therapeutics had a negative return on equity of 22.39% and a negative net margin of 36.39%. As a group, research analysts anticipate that Arcturus Therapeutics Holdings Inc. will post -2.22 EPS for the current fiscal year.

Analyst Ratings Changes

ARCT has been the subject of several research analyst reports. Scotiabank initiated coverage on Arcturus Therapeutics in a research report on Wednesday, May 28th. They issued a “sector outperform” rating and a $32.00 price objective for the company. Canaccord Genuity Group decreased their price objective on Arcturus Therapeutics from $68.00 to $66.00 and set a “buy” rating for the company in a research report on Tuesday, May 13th. BTIG Research set a $48.00 price objective on Arcturus Therapeutics and gave the company a “buy” rating in a research report on Monday, March 10th. Wall Street Zen raised Arcturus Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, May 22nd. Finally, Wells Fargo & Company reduced their price target on Arcturus Therapeutics from $50.00 to $45.00 and set an “overweight” rating for the company in a research report on Wednesday, May 14th. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Arcturus Therapeutics presently has a consensus rating of “Buy” and an average target price of $53.50.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.